Labs 101 – Testosterone & Steroids – What you and your doctor need to know

Member Access Required

Already a member? Sign In

Timeline

00:00

Laboratory planning is introduced as a practical checklist for men using testosterone or steroids. The goal is building a repeatable panel that supports safer long term monitoring.

00:59

The complete blood count is explained as a baseline look at white cells, red cells, and platelets. Hemoglobin and hematocrit targets are emphasized because androgen exposure can raise them.

01:57

Rising red cell measures are tied to polycythemia and possible thrombotic complications over time. Symptoms and individualized hematology guidance are recommended instead of chasing numbers alone.

05:55

The comprehensive metabolic panel section begins by separating routine electrolytes from organ focused markers. Kidney assessment is discussed with caution because creatinine estimates can mislead very muscular bodies.

06:14

Risk factors like hypertension and long term NSAID exposure are mentioned as accelerants of kidney injury. Additional tests such as cystatin C are suggested when standard estimates feel unreliable.

08:45

Liver markers are reviewed with a warning that oral steroids can elevate transaminases noticeably. Mild bilirubin increases are discussed, including a pattern that can match Gilbert syndrome in many men.

09:14

Glucose control is framed as foundational health, not an optional add on to performance goals. Hemoglobin A1c thresholds are reviewed to define prediabetes and type two diabetes clearly.

09:37

PSA testing is emphasized as a prostate screening tool that should be trended over time. Testosterone is framed as not causing prostate cancer, yet existing disease could be accelerated if ignored.

10:59

The lipid panel segment connects total cholesterol, LDL, triglycerides, and HDL to coronary risk. Coronary artery calcium scoring and cardiology input are suggested for intermediate risk decisions.

13:31

The closing recap lists the core panel and encourages early specialist involvement when results drift. Working with cardiology, nephrology, and urology is framed as prevention, not overreaction.

Video Summary

Laboratory monitoring is presented as essential for men using testosterone or anabolic steroids regularly. The framework begins with a core panel that can be repeated and trended over time. A complete blood count is described as the first screen for red cells and platelets. A comprehensive metabolic panel is added to evaluate kidney markers, liver markers, and glucose status. Hemoglobin A1c is highlighted for detecting prediabetes or type two diabetes early. Urinalysis is included to look for protein or blood that suggests kidney stress. PSA and a lipid panel are listed as routine checkpoints for prostate and cardiovascular risk.

The complete blood count section focuses on hemoglobin and hematocrit rising during androgen exposure. Polycythemia is discussed as an outcome that can increase risk for stroke and heart attack. Symptoms like headaches, vision changes, and flushing are mentioned as reasons to seek urgent evaluation. Sleep apnea is raised as a contributor that can push red blood cell production higher. Genetic issues such as hereditary hemochromatosis are mentioned during deeper iron studies discussion. Specialty collaboration with hematology and other clinicians is encouraged when numbers trend upward. Phlebotomy is described as an option that should be individualized, not used indiscriminately.

The metabolic panel discussion turns toward kidney assessment and the limits of creatinine estimates in muscular bodies. Hypertension and frequent nonsteroidal anti inflammatory use are described as additional kidney risk factors. Liver function is reviewed with a warning that oral steroids can raise transaminases significantly. Mild bilirubin elevation is described as sometimes consistent with Gilbert syndrome in many men. Glucose control is tied to hemoglobin A1c targets, with prediabetes defined between 5.7 and 6.4 percent. PSA monitoring is emphasized because testosterone may accelerate an existing prostate cancer if present. Lipid panels and coronary calcium scoring are suggested to refine heart disease risk and guide statin decisions.

Drug Callouts

Testosterone

Testosterone is an androgen hormone prescribed for deficiency and monitored with periodic laboratory testing. The discussion treats testosterone as a common baseline exposure that requires careful lab surveillance.

Statin

Statin therapy refers to cholesterol lowering medications used to reduce cardiovascular event risk. Statins are mentioned as part of risk management when lipid results and overall assessment justify treatment.

Condition Callouts

Hypertension

Hypertension is persistently elevated blood pressure that damages arteries and organs over time. The discussion lists hypertension as a key risk factor to address while monitoring labs.

Chronic kidney disease

Chronic kidney disease is lasting impairment of kidney filtration that can worsen silently. Kidney disease evaluation is emphasized when creatinine estimates and urinalysis findings raise concern.

Liver disease

Liver disease refers to conditions that impair liver function or cause persistent enzyme abnormalities. The segment warns that oral steroids can raise transaminases and require careful follow up.

Prediabetes

Prediabetes is elevated blood sugar that does not yet meet diabetes diagnostic thresholds. Hemoglobin A1c between 5.7 and 6.4 percent is described as the prediabetes range.

Type 2 diabetes

Type 2 diabetes is a metabolic disorder with high blood sugar driven by insulin resistance. Hemoglobin A1c above 6.4 percent is cited as consistent with type two diabetes.

Polycythemia

Polycythemia is an abnormally high red blood cell level that can increase blood viscosity. Rising hemoglobin and hematocrit on androgens are linked to polycythemia risk in the discussion.

Sleep apnea

Sleep apnea is disrupted breathing during sleep that lowers oxygen levels repeatedly. The conversation notes sleep apnea can contribute to higher red blood cell production over time.

Gilbert syndrome

Gilbert syndrome is a benign genetic condition causing mild unconjugated bilirubin elevation. Mild bilirubin increases are described as common and sometimes consistent with this pattern.

Prostate cancer

Prostate cancer is malignant growth in the prostate that may progress if untreated. PSA monitoring is emphasized because existing prostate cancer could be accelerated during testosterone use.

Colon cancer

Colon cancer is malignancy of the large intestine that can be detected with screening tests. Colon cancer screening is mentioned as part of routine preventive care for long term health.

Key Takeaways

Core monitoring includes CBC, metabolic markers, A1c, urinalysis, PSA, and lipids.
Androgen use can raise hemoglobin and hematocrit, so polycythemia risk must be addressed.
Kidney and liver markers deserve careful interpretation, especially in very muscular bodies.
PSA and cancer screening are treated as essential safeguards during testosterone exposure.
Lipid patterns and coronary risk tools can guide cardiology input and statin decisions.